- Open Access
p38 MAPK, microglial signaling, and neuropathic pain
© Ji and Suter; licensee BioMed Central Ltd. 2007
- Received: 24 August 2007
- Accepted: 01 November 2007
- Published: 01 November 2007
Accumulating evidence over last several years indicates an important role of microglial cells in the pathogenesis of neuropathic pain. Signal transduction in microglia under chronic pain states has begun to be revealed. We will review the evidence that p38 MAPK is activated in spinal microglia after nerve injury and contributes importantly to neuropathic pain development and maintenance. We will discuss the upstream mechanisms causing p38 activation in spinal microglia after nerve injury. We will also discuss the downstream mechanisms by which p38 produces inflammatory mediators. Taken together, current data suggest that p38 plays a critical role in microglial signaling under neuropathic pain conditions and represents a valuable therapeutic target for neuropathic pain management.
- Dorsal Root Ganglion
- Neuropathic Pain
- Nerve Injury
- Dorsal Root Ganglion Neuron
- Mechanical Allodynia
Injuries of the nervous system, including peripheral nervous system (PNS, e.g. peripheral nerves, dorsal root ganglia, and dorsal roots) and central nervous system (CNS, e.g. spinal cord and thalamus), often result in neuropathic pain. These injuries may result from diabetic neuropathy, viral infection, major surgeries (e.g. amputation, thoracotomy), spinal cord injury, and stroke [1–3]. Spontaneous pain, described as shooting, lancinating or burning pain, and mechanical allodynia (painful responses to normally innocuous tactile stimuli) are distinct symptoms of neuropathic pain, although neuropathic pain is also characterized by heat hyperalgesia, mechanical hyperalgesia, and cold allodynia. Neuropathic pain is a consequence of neural plasticity, developed both in the PNS (peripheral sensitization) and CNS (central sensitization). After nerve injury, neuropathic pain can arise from injury discharge at the site of axonal injury and ectopic/spontaneous activity in dorsal root ganglion (DRG) neurons [4–6]. Inflammatory mediators (e.g. cytokines) play a critical role in the generation of spontaneous activity and neuropathic pain. Peripheral nerve injury also induces marked phenotypic changes in DRG neurons [1, 2]. While spontaneous activity from primary afferents drives central sensitization, central sensitization is responsible for persistent neuropathic pain. Central sensitization may also directly drive neuropathic pain in central neuropathic pain conditions caused by spinal cord injury or stroke. Central sensitization is induced by enhanced synaptic strength in the spinal cord and brain regions, due to an increase in excitatory synaptic transmission (e.g. AMPA and NMDA currents) or/and a reduction in inhibitory synaptic transmission (e.g. GABA currents) [7–9]. In addition to increased primary afferent input, enhanced descending facilitation also contributes to spinal neuron hypersensitivity and neuropathic pain [10, 11].
Despite our intensive investigation on neuronal mechanisms of neuropathic pain, current treatment has only resulted in limited success. Most analgesics are designed to block neurotransmission, but pain rapidly comes back after drug effects wear off. This is because many "inflammatory mediators (IFMs)" are still produced to activate nociceptive neurons in the PNS and CNS, causing pain hypersensitivity. These IFMs include proinflammatory cytokines [interleukin-1beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNFα)], prostaglandin E2 (PGE2), nitric oxide, nerve growth factor, etc. Unlike neurotransmitters, these IFMs are mainly produced by non-neuronal cells. The IFMs are produced not only at the site of nerve injury by Schwann cells, keratinocytes and immune cells, but also by glial cells in the spinal cord. Microglia are regarded as a main source of IFMs in the CNS [12, 13]. Although brain-derived neurotrophic factor (BDNF) is not regarded as an IFM, it is produced by microglia and plays important role in neuropathic pain development . Thus our list of IFMs also includes BDNF. Since IFMs produced by spinal microglia are crucial to the development of central sensitization and neuropathic pain (see below), it is extremely important to know how these IFMs are produced in microglia. We will summarize the data showing that p38 MAPK is a key regulator of IFM synthesis and release in microglia and also an essential contributor to neuropathic pain sensitization.
Microglia and neuropathic pain
Although glial cells were originally regarded as supporting cells in the CNS, mounting evidence indicates that glia actively communicate with neurons and contribute importantly to the development of different types of neurodegenerative diseases. Increasing evidence also suggests that glial cells in the spinal cord play an important role in pain facilitation [13, 15–17]. For example, peripheral nerve injury produces profound changes in glial cells including morphological changes of microglia and astrocytes and increased expression of glial markers, such as CD11b, Iba-1 and GFAP . Glia inhibitors or glia modifying drugs such as fluorocitrate and propentofylline can alter pain sensitivity [19–21]. While these early studies are important to demonstrate an overall role of glia in regulating pain sensitivity, they did not distinguish which type of glial cells is important in pain regulation.
Among three types of glial cells in the CNS, although oligodendrocytes and astrocytes are found in close apposition to neurons, microglia have gained more attention, in part because nerve injury-induced microglial changes are much more robust than that of oligodendrocytes and astrocytes. A recent microarray study shows that the most regulated genes following nerve injury are expressed in spinal microglia . Nerve injury also induces a profound proliferation of spinal microglia . Current studies on microglial regulation of pain are limited by the lack of specific markers for microglial activation. CD11b and Iba-1 are two of the most used markers for demonstrating microglial activation. However, whether CD11b and Iba-1 contribute to pain hypersensitivity remains unclear. Fortunately, nerve injury up regulates the ATP receptor P2X4 and the chemokine receptor CX3CR1 specifically in spinal microglia, and blocking these receptors results in decreased neuropathic pain [24–26]. The chemokine receptor CCR2 and Toll-like receptor-4 are also expressed in spinal microglia and contribute to neuropathic pain sensitization [27, 28]. Different types of nerve injuries all induce complement cascade in spinal microglia, and mice null for C5 terminal complement component exhibit reduced neuropathic pain sensitivity . Further, minocycline, a microglial inhibitor was shown to prevent or delay neuropathic pain [29, 30]. In particular, intrathecal injection of ATP-activated microglia induces mechanical allodynia, indicating that microglial activation is sufficient to induce pain sensitization . Activation of P2X4 receptor is likely to mediate neuropathic pain by producing BDNF in microglia .
Activation of p38 MAPK in spinal microglia and neuropathic pain
The mitogen-activated protein kinases (MAPKs) are a family of evolutionally conserved molecules that play a critical role in cell signaling and gene expression. MAPK family includes three major members: extracellular signal-regulated kinase (ERK), p38, and c-Jun N-terminal kinase (JNK), representing three different signaling cascades. MAPKs are activated by phosphorylation and transduce a broad range of extracellular stimuli into diverse intracellular responses by both transcriptional and non-transcriptional regulation. p38 MAPK, which is activated by upstream kinase MKK3/MMK6, is regarded as a stress-induced kinase and plays a critical role in inflammatory responses. p38 inhibitor was shown to effectively alleviate rheumatoid arthritis and inflammatory pain [31–33].
We have also examined p38 activation at different times following nerve injury. After SNL, p38 activation in spinal microglia begins on day one and peaks on day 3. It is noteworthy that the increase in p-p38 levels is maintained in spinal microglia even after 3 weeks, despite the fact that at this late time point p-p38 levels decline from the peak levels . Although most studies confirm a specific microglial activation of p38 in the spinal cord, we do not exclude the possibility that moderate p38 activation may also be observed in other spinal cell types when different species or treatment conditions are tested.
p38 inhibition and neuropathic pain
Mounting evidence indicates that p38 activation plays an important role in the development of neuropathic pain. Daily administration of the p38 inhibitor SB203580 intrathecally (i.t.) prevents SNL-induced mechanical allodynia [34, 35]. p38 inhibitors FR167653 or CNI-1493 (i.t.) also prevents the development neuropathic pain symptoms in the spared nerve injury model  and in a sciatic inflammatory neuropathy model .
Nevertheless, the peak activation of p38 and microglia in the spinal cord occurs in the first several days of nerve injury, varying from 3 days to 2 weeks due to different injury conditions [43, 48]. After its peak, p38 and microglial activation starts to decrease significantly, although still maintained at elevated levels at 3 weeks. In contrast, the peak activation of astrocytes in the spinal cord persists for a longer period . Therefore, microglia are probably more important for the early development of neuropathic pain, although they are also involved in the maintenance of neuropathic pain.
There are four different p38 isoforms: α, β, γ and δ. α and β are two of the major isoforms in the mature nervous system  and their activated forms are recognized by commercial p-p38 antibodies. While p38α is the most abundant isoform and expressed in DRG neurons (unpublished observation), p38β appears to be expressed in spinal microglia . Current p38 inhibitors are not isoform-specific due to their design to target common-ATP binding sites on the kinases and structural similarities between the p38 isoforms. To explore the distinct role of p38 isoforms in the development of neuropathic pain, it is important to specifically inhibit a particular isoform. More importantly, isoform-specific inhibition will minimize the side effects produced by blocking all p38 isoforms with a general inhibitor. Interestingly, it has been shown that knockdown of p38β but not p38α with antisense oligonucleotides prevents acute pain sensitization . However, the respective role of p38α and p38β in chronic pain conditions has not been examined. Also, therapeutic enthusiasm for antisense oligonucleotides is not high due to their low efficacy and specificity. A new strategy, such as RNA interference, may be helpful to develop potent and selective knock down of a specific isoform of p38.
How does peripheral nerve injury activate p38 in spinal microglia?
Several studies began to explore the upstream mechanisms causing p38 activation in spinal microglia [26, 36, 50, 51]. TNFα inhibitor prevents neuropathic pain development by inhibiting spinal p38 activation . Spinal p38 is activated by intrathecal infusion of IL-1β and substance P, and p38 inhibitor abolishes the hyperalgesia produced by IL-1β and substance P [50, 51]. In particular, recent studies have demonstrated that chemokines play important roles in mediating neural-glial interaction and neuropathic pain sensitization. Nerve injury induces an up-regulation of the chemokine MCP-1 in primary sensory neurons [48, 52]. Interestingly, CCR2, one type of receptors for MCP-1, was expressed in spinal microglia; spinal p38 activation after nerve injury is reduced in CCR-2 null mice .
Unlike other chemokines that have multiple receptors, fractalkine (FKN), also called CX3CL1, only has one known receptor, CX3CR1. It is of great interest that the CX3CR1 receptor is expressed in spinal microglia and further upregulated after nerve injury [25, 26]. On the other hand, FKN is primarily produced in DRG and dorsal horn neurons . FKN has 2 forms, a membrane-bound form (large size) and a soluble form (small size) that mediate cell adhesion and chemotaxis, respectively. FKN is normally membrane-bound, but this membrane-bound FKN in the DRG is cleaved after nerve injury, leading to the release of FKN . A recent study shows that cysteine protease cathepsin S (CatS), which is produced in microglia after nerve injury, can enhance neuropathic pain by cleavage of FKN on the membrane of DRG neurons. CatS-induced hyperalgesia is lost in CX3CR1 null mice . FKN can also be cleaved by metalloproteinases (MMPs), such as MMP-9 that is released from DRG neurons after nerve injury (Xu and Ji, unpublished observation). Intrathecal infusion of FKN not only induces mechanical allodynia but also activates p38 in spinal microglia . Perfusion of spinal cord slices with FKN activates p38 in microglia . Conversely, a neutralizing antibody against CX3CR1 reduces both p38 activation and neuropathic pain . Thus, FKN-CX3CR1-p38 cascade is required for the development of neuropathic pain.
After peripheral nerve injury, spontaneous activity (ectopic discharge), which is crucial for the genesis of neuropathic pain, can be recorded in axons as well as in DRG soma. Is this spontaneous activity required for p38 activation in spinal microglia? To produce long-term blockade of nerve activity, we applied bupivacaine microspheres to the sciatic nerve, which produces a persistent (> 1 week) conduction blockade due to slow release of bupivacaine . Using this method for long-term blockade, we found that spontaneous activity is fully required to initiate p38 activation in spinal microglia. However, nerve conduction blockade does not reverse p38 activation when applied after nerve injury . It is suggested that after initiation, microglia activation could be self-maintained given that multiple mediators released by microglia can also feed back to microglia via an autocrine or paracrine fashion. Since FKN released from neurons triggers microglial activation, it remains to be tested whether spontaneous activity after nerve injury can induce the cleavage of FKN.
p38 and microglial signaling
How does p38 activation in spinal microglia result in pain hypersensitivity? As mentioned above, activated microglia produce numerous IFMs (e.g., IL-1β, IL-6, TNFα, PGE2, NO, BDNF), which are also produced in the spinal cord after nerve injury. All of these IFMs are implicated in pain facilitation [13–17, 44, 54, 55].
p38 is known to regulate the synthesis of numerous IFMs via transcriptional regulation [31, 32]. For example, SNL-induced IL-1β up-regulation is attenuated by spinal inhibition of p38 (Fig 2b). Especially, p38 has been shown to activate the transcription factor NF-κB in cultured microglia [56, 57], leading to the expression of the IL-1β, IL-6, and COX-2 . Interestingly, NF-κB is upregulated in spinal microglia after nerve injury (unpublished observation). Although it was traditionally believed that COX-1 is constitutively expressed while COX-2 is inducible, COX-1 was shown to be induced in spinal microglia after SNL  and COX-1 inhibitor can attenuate neuropathic pain . It is worthy to investigate whether p38 is required for this upregulation. p38 activation after intrathecal IL-1β is required for the synthesis of iNOS . In addition to p38 activation in spinal microglia, we found that ERK, another MAPK family member, is also activated in spinal microglia at early times (first several days) of neuropathic pain development, which is required for neuropathic pain sensitization . p38 and ERK appear to be activated in different populations of spinal microglia. It is likely that the ERK and p38 pathways can act together to regulate neuropathic pain. For example, a combination of MEK and p38 inhibitors has been shown to suppress endotoxin-induced expression of iNOS and TNFα in microglia with a much greater efficacy than each inhibitor alone .
p38 can also regulate the synthesis of IFMs by posttranslational regulation. For example, p38 activates phospholipase A2 (PLA2) via its downstream kinase MAPKAP-2 (MAPK activated protein kinase-2). PLA2 plays an important role in inflammatory responses. The activation of PLA2 results in the genesis of arachidonic acid for prostaglandin production, which can be catalyzed via COX to produce PGE2 . Several PLA2 forms are expressed in spinal cord, and inhibiting spinal PLA2 induces a potent antihyperalgesia . PGE2 release evoked by intrathecal dynorphin requires spinal p38 activation . p38 activation also causes a rapid release of IL-1β from spinal microglia. For example, following application of lipopolysaccharide to an ex vivo spinal slice preparation, there is a rapid activation of p38 in spinal microglia and a rapid secretion of IL-1β. Further, IL-1β secretion is prevented by p38 inhibitor .
Concluding remarks and future directions
Currently, most people use CD11b or IBA-1 as markers for microglial activation. Although these are specific markers and show profound changes after injuries, their roles in neuropathic pain have not been clearly addressed, due to the lack of specific tools to block the action of these markers. In several cases, neuropathic pain is dissociated with CD11b expression [24, 66]. Thus additional markers are needed to demonstrate microglia activation. Phosphorylated MAPKs (e.g. p-p38 or pERK) can be used as extra markers to reflect the activity of microglia after nerve injury, because phosphorylation is very rapid and sensitive in response to changes in cellular environment.
Can p38 inhibitors be used to treat clinical pain? Many pharmaceutical companies have been trying to develop specific p38 inhibitors. Several p38 MAPK inhibitors including SB281838, BIRB0796, Ro320-1195, and SCIO-469 have been tested in clinical trials for inflammatory diseases such as rheumatoid arthritis as well as for cancer [67, 68]. Given that p38 is a critical contributor in several chronic pain conditions, p38 inhibitors should also be tested for clinical pain. A major concern is p38 inhibitors may produce psychiatric and cardiovascular side effects or liver toxicity. Development of more specific p38 inhibitors, such as activation status-specific inhibitors and isoform-specific inhibitors is highly demanded. Local delivery of p38 inhibitors or siRNA strategy may also be considered.
The work was supported in part by NIH grants NS40698, DE17794, and TW7180, and by the Swiss National Science Foundation PBLAB118504.
- Ji RR, Strichartz G: Cell signaling and the genesis of neuropathic pain. Sci STKE 2004, 2004: reE14.PubMedGoogle Scholar
- Kehlet H, Jensen TS, Woolf CJ: Persistent postsurgical pain: risk factors and prevention. Lancet 2006, 367: 1618–1625. 10.1016/S0140-6736(06)68700-XPubMedView ArticleGoogle Scholar
- Woolf CJ, Mannion RJ: Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999, 353: 1959–1964. 10.1016/S0140-6736(99)01307-0PubMedView ArticleGoogle Scholar
- Devor M, Seltzer Z: Pathophysiology of damaged nerves in relation to chronic pain. In Textbook of Pain. Volume 5. 4th edition. Edited by: Wall PD and Melzack R. Edinburgh, Churchill Livingstone; 1999:129–164.Google Scholar
- Ma C, Shu Y, Zheng Z, Chen Y, Yao H, Greenquist KW, White FA, LaMotte RH: Similar electrophysiological changes in axotomized and neighboring intact dorsal root ganglion neurons. J Neurophysiol 2003, 89: 1588–1602. 10.1152/jn.00855.2002PubMedView ArticleGoogle Scholar
- Wu G, Ringkamp M, Hartke TV, Murinson BB, Campbell JN, Griffin JW, Meyer RA: Early onset of spontaneous activity in uninjured C-fiber nociceptors after injury to neighboring nerve fibers. J Neurosci 2001, 21: RC140.PubMedGoogle Scholar
- Woolf CJ, Salter MW: Neuronal plasticity: increasing the gain in pain. Science 2000, 288: 1765–1769. 10.1126/science.288.5472.1765PubMedView ArticleGoogle Scholar
- Ji RR, Kohno T, Moore KA, Woolf CJ: Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci 2003, 26: 696–705. 10.1016/j.tins.2003.09.017PubMedView ArticleGoogle Scholar
- Coull JA, Boudreau D, Bachand K, Prescott SA, Nault F, Sik A, De Koninck P, De Koninck Y: Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain. Nature 2003, 424: 938–942. 10.1038/nature01868PubMedView ArticleGoogle Scholar
- Porreca F, Ossipov MH, Gebhart GF: Chronic pain and medullary descending facilitation. Trends Neurosci 2002, 25: 319–325. 10.1016/S0166-2236(02)02157-4PubMedView ArticleGoogle Scholar
- Zhuo M: Neuronal mechanism for neuropathic pain. Mol Pain 2007, 3: 14. 10.1186/1744-8069-3-14PubMed CentralPubMedView ArticleGoogle Scholar
- Hanisch UK: Microglia as a source and target of cytokines. Glia 2002, 40: 140–155. 10.1002/glia.10161PubMedView ArticleGoogle Scholar
- Tsuda M, Inoue K, Salter MW: Neuropathic pain and spinal microglia: a big problem from molecules in "small" glia. Trends Neurosci 2005, 28: 101–107. 10.1016/j.tins.2004.12.002PubMedView ArticleGoogle Scholar
- Coull JA, Beggs S, Boudreau D, Boivin D, Tsuda M, Inoue K, Gravel C, Salter MW, De Koninck Y: BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 2005, 438: 1017–1021. 10.1038/nature04223PubMedView ArticleGoogle Scholar
- Watkins LR, Milligan ED, Maier SF: Glial activation: a driving force for pathological pain. Trends Neurosci 2001, 24: 450–455. 10.1016/S0166-2236(00)01854-3PubMedView ArticleGoogle Scholar
- DeLeo JA, Yezierski RP: The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 2001, 90: 1–6. 10.1016/S0304-3959(00)00490-5PubMedView ArticleGoogle Scholar
- Marchand F, Perretti M, McMahon SB: Role of the immune system in chronic pain. Nat Rev Neurosci 2005, 6: 521–532. 10.1038/nrn1700PubMedView ArticleGoogle Scholar
- Garrison CJ, Dougherty PM, Kajander KC, Carlton SM: Staining of glial fibrillary acidic protein (GFAP) in lumbar spinal cord increases following a sciatic nerve constriction injury. Brain Res 1991, 565: 1–7. 10.1016/0006-8993(91)91729-KPubMedView ArticleGoogle Scholar
- Watkins LR, Martin D, Ulrich P, Tracey KJ, Maier SF: Evidence for the involvement of spinal cord glia in subcutaneous formalin induced hyperalgesia in the rat. Pain 1997, 71: 225–235. 10.1016/S0304-3959(97)03369-1PubMedView ArticleGoogle Scholar
- Meller ST, Dykstra C, Grzybycki D, Murphy S, Gebhart GF: The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat. Neuropharmacology 1994, 33: 1471–1478. 10.1016/0028-3908(94)90051-5PubMedView ArticleGoogle Scholar
- Sweitzer SM, Schubert P, DeLeo JA: Propentofylline, a glial modulating agent, exhibits antiallodynic properties in a rat model of neuropathic pain. J Pharmacol Exp Ther 2001, 297: 1210–1217.PubMedGoogle Scholar
- Griffin RS, Costigan M, Brenner GJ, Ma CH, Scholz J, Moss A, Allchorne AJ, Stahl GL, Woolf CJ: Complement induction in spinal cord microglia results in anaphylatoxin C5a-mediated pain hypersensitivity. J Neurosci 2007, 27: 8699–8708. 10.1523/JNEUROSCI.2018-07.2007PubMedView ArticleGoogle Scholar
- Echeverry S, Shi XQ, Zhang J: Characterization of cell proliferation in rat spinal cord following peripheral nerve injury and the relationship with neuropathic pain. Pain 2007.Google Scholar
- Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, Inoue K: P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 2003, 424: 778–783. 10.1038/nature01786PubMedView ArticleGoogle Scholar
- Verge GM, Milligan ED, Maier SF, Watkins LR, Naeve GS, Foster AC: Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur J Neurosci 2004, 20: 1150–1160. 10.1111/j.1460-9568.2004.03593.xPubMedView ArticleGoogle Scholar
- Zhuang ZY, Kawasaki Y, Tan PH, Wen YR, Huang J, Ji RR: Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine. Brain Behav Immun 2007, 21: 642–651. 10.1016/j.bbi.2006.11.003PubMed CentralPubMedView ArticleGoogle Scholar
- Abbadie C, Lindia JA, Cumiskey AM, Peterson LB, Mudgett JS, Bayne EK, DeMartino JA, MacIntyre DE, Forrest MJ: Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc Natl Acad Sci U S A 2003, 100: 7947–7952. 10.1073/pnas.1331358100PubMed CentralPubMedView ArticleGoogle Scholar
- Tanga FY, Nutile-McMenemy N, DeLeo JA: The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy. Proc Natl Acad Sci U S A 2005, 102: 5856–5861. 10.1073/pnas.0501634102PubMed CentralPubMedView ArticleGoogle Scholar
- Raghavendra V, Tanga F, DeLeo JA: Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther 2003, 306: 624–630. 10.1124/jpet.103.052407PubMedView ArticleGoogle Scholar
- Ledeboer A, Sloane EM, Milligan ED, Frank MG, Mahony JH, Maier SF, Watkins LR: Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain 2005, 115: 71–83. 10.1016/j.pain.2005.02.009PubMedView ArticleGoogle Scholar
- Kumar S, Boehm J, Lee JC: p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003, 2: 717–726. 10.1038/nrd1177PubMedView ArticleGoogle Scholar
- Ji RR, Woolf CJ: Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain. Neurobiol Dis 2001, 8: 1–10. 10.1006/nbdi.2000.0360PubMedView ArticleGoogle Scholar
- Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ: p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002, 36: 57–68. 10.1016/S0896-6273(02)00908-XPubMedView ArticleGoogle Scholar
- Jin SX, Zhuang ZY, Woolf CJ, Ji RR: p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci 2003, 23: 4017–4022.PubMedGoogle Scholar
- Tsuda M, Mizokoshi A, Shigemoto-Mogami Y, Koizumi S, Inoue K: Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. Glia 2004, 45: 89–95. 10.1002/glia.10308PubMedView ArticleGoogle Scholar
- Svensson CI, Schafers M, Jones TL, Powell H, Sorkin LS: Spinal blockade of TNF blocks spinal nerve ligation-induced increases in spinal P-p38. Neurosci Lett 2005, 379: 209–213. 10.1016/j.neulet.2004.12.064PubMedView ArticleGoogle Scholar
- Katsura H, Obata K, Mizushima T, Sakurai J, Kobayashi K, Yamanaka H, Dai Y, Fukuoka T, Sakagami M, Noguchi K: Activation of Src-family kinases in spinal microglia contributes to mechanical hypersensitivity after nerve injury. J Neurosci 2006, 26: 8680–8690. 10.1523/JNEUROSCI.1771-06.2006PubMedView ArticleGoogle Scholar
- Wen YR, Suter MR, Kawasaki Y, Huang J, Pertin M, Kohno T, Berde CB, Decosterd I, Ji RR: Nerve Conduction Blockade in the Sciatic Nerve Prevents but Does Not Reverse the Activation of p38 Mitogen-activated Protein Kinase in Spinal Microglia in the Rat Spared Nerve Injury Model. Anesthesiology 2007, 107: 312–321. 10.1097/01.anes.0000270759.11086.e7PubMedView ArticleGoogle Scholar
- Xu JT, Xin WJ, Wei XH, Wu CY, Ge YX, Liu YL, Zang Y, Zhang T, Li YY, Liu XG: p38 activation in uninjured primary afferent neurons and in spinal microglia contributes to the development of neuropathic pain induced by selective motor fiber injury. Exp Neurol 2007, 204: 355–365. 10.1016/j.expneurol.2006.11.016PubMedView ArticleGoogle Scholar
- Hains BC, Waxman SG: Activated microglia contribute to the maintenance of chronic pain after spinal cord injury. J Neurosci 2006, 26: 4308–4317. 10.1523/JNEUROSCI.0003-06.2006PubMedView ArticleGoogle Scholar
- Boyle DL, Jones TL, Hammaker D, Svensson CI, Rosengren S, Albani S, Sorkin L, Firestein GS: Regulation of peripheral inflammation by spinal p38 MAP kinase in rats. PLoS Med 2006, 3: e338. 10.1371/journal.pmed.0030338PubMed CentralPubMedView ArticleGoogle Scholar
- Cui Y, Chen Y, Zhi JL, Guo RX, Feng JQ, Chen PX: Activation of p38 mitogen-activated protein kinase in spinal microglia mediates morphine antinociceptive tolerance. Brain Res 2006, 1069: 235–243. 10.1016/j.brainres.2005.11.066PubMedView ArticleGoogle Scholar
- Zhuang ZY, Wen YR, Zhang DR, Borsello T, Bonny C, Strichartz GR, Decosterd I, Ji RR: A peptide c-Jun N-terminal kinase (JNK) inhibitor blocks mechanical allodynia after spinal nerve ligation: respective roles of JNK activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenance. J Neurosci 2006, 26: 3551–3560. 10.1523/JNEUROSCI.5290-05.2006PubMedView ArticleGoogle Scholar
- Milligan ED, Twining C, Chacur M, Biedenkapp J, O'Connor K, Poole S, Tracey K, Martin D, Maier SF, Watkins LR: Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci 2003, 23: 1026–1040.PubMedGoogle Scholar
- Schafers M, Svensson CI, Sommer C, Sorkin LS: Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci 2003, 23: 2517–2521.PubMedGoogle Scholar
- Sweitzer SM, Medicherla S, Almirez R, Dugar S, Chakravarty S, Shumilla JA, Yeomans DC, Protter AA: Antinociceptive action of a p38alpha MAPK inhibitor, SD-282, in a diabetic neuropathy model. Pain 2004, 109: 409–419. 10.1016/j.pain.2004.02.016PubMedView ArticleGoogle Scholar
- Tawfik VL, Nutile-McMenemy N, Lacroix-Fralish ML, DeLeo JA: Efficacy of propentofylline, a glial modulating agent, on existing mechanical allodynia following peripheral nerve injury. Brain Behav Immun 2007, 21: 238–246. 10.1016/j.bbi.2006.07.001PubMedView ArticleGoogle Scholar
- Zhang J, De Koninck Y: Spatial and temporal relationship between monocyte chemoattractant protein-1 expression and spinal glial activation following peripheral nerve injury. J Neurochem 2006, 97: 772–783. 10.1111/j.1471-4159.2006.03746.xPubMedView ArticleGoogle Scholar
- Svensson CI, Fitzsimmons B, Azizi S, Powell HC, Hua XY, Yaksh TL: Spinal p38beta isoform mediates tissue injury-induced hyperalgesia and spinal sensitization. J Neurochem 2005, 92: 1508–1520. 10.1111/j.1471-4159.2004.02996.xPubMedView ArticleGoogle Scholar
- Svensson CI, Marsala M, Westerlund A, Calcutt NA, Campana WM, Freshwater JD, Catalano R, Feng Y, Protter AA, Scott B, Yaksh TL: Activation of p38 mitogen-activated protein kinase in spinal microglia is a critical link in inflammation-induced spinal pain processing. J Neurochem 2003, 86: 1534–1544. 10.1046/j.1471-4159.2003.01969.xPubMedView ArticleGoogle Scholar
- Sung CS, Wen ZH, Chang WK, Chan KH, Ho ST, Tsai SK, Chang YC, Wong CS: Inhibition of p38 mitogen-activated protein kinase attenuates interleukin-1beta-induced thermal hyperalgesia and inducible nitric oxide synthase expression in the spinal cord. J Neurochem 2005, 94: 742–752. 10.1111/j.1471-4159.2005.03226.xPubMedView ArticleGoogle Scholar
- White FA, Sun J, Waters SM, Ma C, Ren D, Ripsch M, Steflik J, Cortright DN, LaMotte RH, Miller RJ: Excitatory monocyte chemoattractant protein-1 signaling is up-regulated in sensory neurons after chronic compression of the dorsal root ganglion. Proc Natl Acad Sci U S A 2005, 102: 14092–14097. 10.1073/pnas.0503496102PubMed CentralPubMedView ArticleGoogle Scholar
- Clark AK, Yip PK, Grist J, Gentry C, Staniland AA, Marchand F, Dehvari M, Wotherspoon G, Winter J, Ullah J, Bevan S, Malcangio M: Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc Natl Acad Sci U S A 2007.Google Scholar
- Winkelstein BA, Rutkowski MD, Sweitzer SM, Pahl JL, DeLeo JA: Nerve injury proximal or distal to the DRG induces similar spinal glial activation and selective cytokine expression but differential behavioral responses to pharmacologic treatment. J Comp Neurol 2001, 439: 127–139. 10.1002/cne.2000PubMedView ArticleGoogle Scholar
- Sweitzer S, Martin D, DeLeo JA: Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. Neuroscience 2001, 103: 529–539. 10.1016/S0306-4522(00)00574-1PubMedView ArticleGoogle Scholar
- Jana M, Dasgupta S, Saha RN, Liu X, Pahan K: Induction of tumor necrosis factor-alpha (TNF-alpha) by interleukin-12 p40 monomer and homodimer in microglia and macrophages. J Neurochem 2003, 86: 519–528. 10.1046/j.1471-4159.2003.01864.xPubMed CentralPubMedView ArticleGoogle Scholar
- Wilms H, Rosenstiel P, Sievers J, Deuschl G, Zecca L, Lucius R: Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. FASEB J 2003, 17: 500–502.PubMedGoogle Scholar
- Krakauer T: Molecular therapeutic targets in inflammation: cyclooxygenase and NF-kappaB. Curr Drug Targets Inflamm Allergy 2004, 3: 317–324. 10.2174/1568010043343714PubMedView ArticleGoogle Scholar
- Zhu X, Eisenach JC: Cyclooxygenase-1 in the spinal cord is altered after peripheral nerve injury. Anesthesiology 2003, 99: 1175–1179. 10.1097/00000542-200311000-00026PubMedView ArticleGoogle Scholar
- Hefferan MP, O'Rielly DD, Loomis CW: Inhibition of spinal prostaglandin synthesis early after L5/L6 nerve ligation prevents the development of prostaglandin-dependent and prostaglandin-independent allodynia in the rat. Anesthesiology 2003, 99: 1180–1188. 10.1097/00000542-200311000-00027PubMedView ArticleGoogle Scholar
- Zhuang ZY, Gerner P, Woolf CJ, Ji RR: ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 2005, 114: 149–159. 10.1016/j.pain.2004.12.022PubMedView ArticleGoogle Scholar
- Bhat NR, Zhang P, Lee JC, Hogan EL: Extracellular signal-regulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-alpha gene expression in endotoxin-stimulated primary glial cultures. J Neurosci 1998, 18: 1633–1641.PubMedGoogle Scholar
- Yaksh TL, Kokotos G, Svensson CI, Stephens D, Kokotos CG, Fitzsimmons B, Hadjipavlou-Litina D, Hua XY, Dennis EA: Systemic and intrathecal effects of a novel series of phospholipase A2 inhibitors on hyperalgesia and spinal prostaglandin E2 release. J Pharmacol Exp Ther 2006, 316: 466–475. 10.1124/jpet.105.091686PubMedView ArticleGoogle Scholar
- Svensson CI, Hua XY, Powell HC, Lai J, Porreca F, Yaksh TL: Prostaglandin E2 release evoked by intrathecal dynorphin is dependent on spinal p38 mitogen activated protein kinase. Neuropeptides 2005, 39: 485–494. 10.1016/j.npep.2005.08.002PubMedView ArticleGoogle Scholar
- Clark AK, D'Aquisto F, Gentry C, Marchand F, McMahon SB, Malcangio M: Rapid co-release of interleukin 1beta and caspase 1 in spinal cord inflammation. J Neurochem 2006, 99: 868–880. 10.1111/j.1471-4159.2006.04126.xPubMedView ArticleGoogle Scholar
- Colburn RW, DeLeo JA, Rickman AJ, Yeager MP, Kwon P, Hickey WF: Dissociation of microglial activation and neuropathic pain behaviors following peripheral nerve injury in the rat. J Neuroimmunol 1997, 79: 163–175. 10.1016/S0165-5728(97)00119-7PubMedView ArticleGoogle Scholar
- Ji RR, Kawasaki Y, Zhuang ZY, Wen YR, Zhang YQ: Protein kinases as potential targets for the treatment of pathological pain. Handb Exp Pharmacol 2007, 359–389.Google Scholar
- Watkins LR, Maier SF: Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Discov 2003, 2: 973–985. 10.1038/nrd1251PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.